Shots:   Myelodysplastic Syndrome (MDS) is a rare and aggressive blood cancer in which the bone marrow fails to produce enough healthy blood cells  As resistance to traditional treatments continues to rise among MDS patients, Faron Pharmaceuticals' Bexmab emerges as a promising alternative  Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, highlights Bexmab’s unique mechanism…